In vivo base editing extends lifespan of a humanized mouse model of prion disease
Nature Medicine · 2025-04 · 31 (4) · 1319-1328
DOI: 10.1038/s41591-024-03466-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature Medicine, online erschienen am 14.01.2025. Verfasst von Meirui An und 26 weiteren Autor:innen. Beteiligte Einrichtung: Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Prion Diseases, Gene Editing, Prion Proteins, Longevity. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCEZID CDC HHS, NHGRI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Prion disease is a fatal neurodegenerative disease caused by the misfolding of prion protein (PrP) encoded by the PRNP gene. While there is currently no cure for the disease, depleting PrP in the brain is an established strategy to prevent or stall templated misfolding of PrP. Here we developed in vivo cytosine and adenine base strategies delivered by adeno-associated viruses to permanently modify the PRNP locus to achieve PrP knockdown in the mouse brain. Systemic injection of dual-adeno-associated virus PHP.eB encoding BE3.9max and single guide RNA installing PRNP R37X resulted in 37% average installation of the desired edit, 50% reduction of PrP in the mouse brain and 52% extension of lifespan in transgenic human PRNP mice inoculated with pathogenic human prion isolates representing the most common sporadic and genetic subtypes of prion disease. We further engineered base editing systems to achieve improved in vivo potency and reduced base editor expression in nontargeting tissues, resulting in 63% average PrP reduction in the mouse brain from a 6.7-fold lower viral dose, with no detected off-target editing of anticipated clinical significance observed in either human cells or mouse tissues. These findings support the potential of in vivo base editing as one-time treatment for prion disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.
- Howard Hughes Medical Institute, Harvard University, Cambridge, MA, USA.
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Comparative Medicine, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Case Western Reserve University, Cleveland, OH, USA.
Förderung
- NCEZID CDC HHS
- NHGRI NIH HHS
- NIGMS NIH HHS
- NIAID NIH HHS
- Howard Hughes Medical Institute (HHMI)
- NINDS NIH HHS
Zitieren
APA
An, M., Davis, J. R., Levy, J. M., Serack, F. E., Harvey, J. W., Brauer, P. P., Pirtle, C. P., Berríos, K. N., Newby, G. A., Yeh, W. H., Kamath, N., Mortberg, M., Lian, Y., Howard, M., DeSouza-Lenz, K., Guzman, K., Thai, A., Graffam, S., Laversenne, V., …, & Liu, D. R. (2025). In vivo base editing extends lifespan of a humanized mouse model of prion disease. Nature Medicine, 31(4), 1319-1328. https://doi.org/10.1038/s41591-024-03466-w
Vancouver
An M, Davis JR, Levy JM, Serack FE, Harvey JW, Brauer PP, et al. In vivo base editing extends lifespan of a humanized mouse model of prion disease. Nature Medicine. 2025;31(4):1319-1328. doi:10.1038/s41591-024-03466-w
BibTeX
@article{An2025,
author = {An, Meirui and Davis, Jessie R and Levy, Jonathan M and Serack, Fiona E and Harvey, John W and Brauer, Pamela P and Pirtle, Catherine P and Berríos, Kiara N and Newby, Gregory A and Yeh, Wei-Hsi and Kamath, Nikita and Mortberg, Meredith and Lian, Yuan and Howard, Michael and DeSouza-Lenz, Kendrick and Guzman, Kenia and Thai, Aaron and Graffam, Samantha and Laversenne, Vanessa and Coffey, Alissa A and Frei, Jeannine and Pierce, Sarah E and Safar, Jiri G and Deverman, Benjamin E and Minikel, Eric Vallabh and Vallabh, Sonia M and Liu, David R},
title = {In vivo base editing extends lifespan of a humanized mouse model of prion disease},
journal = {Nature Medicine},
year = {2025},
volume = {31},
number = {4},
pages = {1319--1328},
doi = {10.1038/s41591-024-03466-w}
}
EUVIMED